[Seasonal and Perennial Allergic Rhinoconjunctivitis]
- PMID: 28291999
- DOI: 10.1055/s-0043-101391
[Seasonal and Perennial Allergic Rhinoconjunctivitis]
Abstract
Seasonsal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC) as well as intermittent and persistent allergic rhinitis are widespread diseases. Because a combined occurrence of ocular and nasal symptoms is very common the summarising term allergic rhinoconjunctivitis is frequently used. SAC and PAC representing the two acute forms of allergic conjunctivitis account for more than 90% of all cases of allergic conjunctivitis. Compared to the chronic forms of allergic conjunctivitis their course of disease is milder. Nevertheless because of their high prevalence and the proven influence on patients' quality of life they possess clinical and socioeconomic relevance. Allergic rhinoconjunctivitis is caused by a type 1 IgE-mediated hypersensitivitity reaction that is provoked by aeroallergens in the majority of cases. The pathognomonic sign is itching. Besides, typical ocular findings are chemosis, conjunctival injection,watery secretion and lid swelling. Otorhinolaryngologists' findings include rhinorrhea, postnasal drip and sneezing. Problems in breathing through the nose resulting from nasal obstruction can cause impaired nighttime sleep and daytime somnolence. In addition to a reduction of allergen exposure by modification of environment and life style factors, in mild forms of SAC and PAC artificial tears are recommended. Topical antihistamines can generate rapid relief from acute symptoms and itching. Topical mast cell stabilisers however provide long-term effects. Dual action drugs that combine antihistamines and mast cell stabilisers show increased patient compliance due to reduced application frequency. Use of topical steroids should be cautious and only temporary. For prolonged treatment periods unpreserved anti-allergic eye-drops should be preferred. Combined topical antihistamines and new-generation topical nasal steroids often used by otorhinolaryngologists demonstrate a good safety profile without systemic side effects. In summary, allergic rhinoconjunctivitis represents a common disease pattern that can be treated effectively. Once it is diagnosed correctly targeted treatment results in improved patients' quality of life quickly.
© Georg Thieme Verlag KG Stuttgart · New York.
Similar articles
-
[Seasonal and perennial allergic rhinoconjunctivitis].Klin Monbl Augenheilkd. 2014 May;231(5):496-504. doi: 10.1055/s-0034-1368397. Epub 2014 May 5. Klin Monbl Augenheilkd. 2014. PMID: 24799168 Review. German.
-
Evolving paradigm in the management of allergic rhinitis-associated ocular symptoms: role of intranasal corticosteroids.Curr Med Res Opin. 2008 Mar;24(3):821-36. doi: 10.1185/030079908X253780. Epub 2008 Feb 6. Curr Med Res Opin. 2008. PMID: 18257976 Review.
-
A comparison of the relative clinical efficacy of a single dose of ketotifen fumarate 0.025% ophthalmic solution versus placebo in inhibiting the signs and symptoms of allergic rhinoconjunctivitis as induced by the conjunctival allergen challenge model.Clin Ther. 2002 Nov;24(11):1800-8. doi: 10.1016/s0149-2918(02)80080-7. Clin Ther. 2002. PMID: 12501875 Clinical Trial.
-
[Allergic rhinoconjunctivitis--past and present aspects].Monatsschr Kinderheilkd. 1992 Mar;140(3):156-61. Monatsschr Kinderheilkd. 1992. PMID: 1603098 Review. German.
-
Levocabastine: a new topical approach for the treatment of paediatric allergic rhinoconjunctivitis.Rhinol Suppl. 1992 Sep;13:39-49. Rhinol Suppl. 1992. PMID: 1358140 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical